Technology

Our Technology: pioneer and expert to manufacture a unique and a potent stem cell drug

Highest quality stem cells using our in-house developed and validated GMP manufacturing process and quality control to generate a defined and unique stem cell in accordance with the AMG (German Medicinal Products Act) to produce an ATMP (Advanced Therapy Medicinal Product).

Drug development based on ABCB5+ mesenchymal stem cells
Drug development based on ABCB5+ mesenchymal stem cells

TICEBA has exclusive license to the full patent portfolio on the ABCB5 gene and protein family from Boston Children's Hospital, a teaching affiliate of Harvard Medical School, Boston, Massachusetts (37+ exclusive patents).

Our groundbreaking ABCB5 researches have received widespread coverage in peer-reviewed academic journals, leading to high-end developed Potency Assays to translate research into clinical efficacy.

Off the shelf & ready to use: covering the full spectrum of clinical development from CMC to the market

High throughput stem cell production with worldwide patented technology and proprietary know-how serving market needs - anytime and anywhere.

Established and Approved Technology with high Potential: Ready for Next Generation Cell Therapeutics

Using our established and patented technology platform to feed the next generation technologies (CRISPR/Cas, iPS Technology, 3D Bioprinting...) to develop next generation of Cell Therapeutics.

a Agency Regulated tissue removal centers
b Patented technology: 37 patents exclusive with Harvard University
c Ballikaya et al., Stem Cell Res Ther. 2020 / Kerstan et a., Cytotherapy. 2021
d Isolation of ABCB5-positive Mesenchymal Stem Cells